Table 2.

Relative risks of Premature Onset of CVD for the e4 Allele Carriers Compared to the Non-e4 Carriers

Cohort	Age group	Gender	N totala	N CVD	RRb	95% CI	P value
FHS	All ages	M&W	1250	804	0.93	0.78–1.11	0.405
		Men	452	322	1.08	0.83–1.41	0.547
		Women	798	482	0.84	0.66–1.07	0.153
FHS	≤75 years	M&W	397	379	1.49	1.18–1.88	7.5E-04
		Men	190	178	1.25	0.90–1.72	0.178
		Women	207	201	1.73	1.24–2.43	1.4E-03
FHS	76+ years	M&W	853	425	0.78	0.60–1.00	0.051
		Men	262	144	0.99	0.68–1.46	0.971
		Women	591	281	0.69	0.50–0.95	0.025
FHSO	All ages	M&W	3867	931	1.22	1.05–1.42	9.0E-03
		Men	1842	569	1.16	0.96–1.41	0.121
		Women	2025	362	1.33	1.05–1.69	0.017
FHSO	>65 years	M&W	2206	388	1.22	0.96–1.54	0.105
		Men	997	210	1.03	0.74–1.41	0.882
		Women	1209	178	1.49	1.06–2.10	0.022
FHS&FHSO	All ages	M&W	5117	1735	1.08	0.96–1.21	0.201
		Men	2294	891	1.13	0.97–1.32	0.130
		Women	2823	844	1.03	0.87–1.22	0.761

Age groups “≤75 years” and “76+ years” denote subjects who have been 75 years or younger and 76 years or older at CVD onset for cases or the end of follow up in 2008 (or death) for censored individuals in the FHS cohort.

Age group “>65 years” denotes subjects who have being older than 65 years at CVD onset for cases or the end of follow up in 2008 (or death) for censored individuals in the FHSO cohort.

Bold font highlights significant and marginally significant results.

^aAll subjects with missing information on onset of either CVD or cancer were excluded.

^bCox regression model was adjusted for age as well as for sex and cohort when applicable.

CVD, Cardiovascular disease; RR, relative risk; CI, confidence interval; FHS, Framingham Heart Study original cohort; FHSO, Framingham Heart Study Offspring cohort; M&W, men and women.